Table 2 Summary of evidence findings table.
Outcome | No.of studies(I/N) | Effect size (MD,95% CI) | P value | I² |
|---|---|---|---|---|
IL-6 | 3 (88/86) | 0.24 pg/mL, [−0.75, 1.23] | 0.64 | 0% |
TNF-a | 2 (63/63) | −5.64 pg/mL, [−15.78, 4.49] | 0.28 | 87% |
CRP | 4 (103/106) | 1.40 mg/L, [−1.33, 4.13] | 0.32 | 58% |
Folate | 2 (61/56) | 0.48 nmol/L, [−0.98,1.93] | 0.52 | 0% |
Ferritin | 2 (57/62) | −14.50 ng/mL, [−39.59, 10.58] | 0.26 | 0% |
Hb | 2 (57/62) | −0.11 g/dL, [−0.40, 0.18] | 0.45 | 18% |
GSRS | 1 (34/39) | −0.34, [−0.46, −0.22] | <0.00001 | N/A |
BES(3 M) | 1 (37/32) | −1.12, [−1.93, −0.31] | 0.007 | N/A |
BES(12 M) | 1 (22/22) | −1.40, [−2.40, −0.40] | 0.006 | N/A |
YFAS(3 M) | 1 (37/32) | −3.29, [−6.86, 0.28] | 0.07 | N/A |
YFAS(12 M) | 1 (22/22) | −5.06, [−9.51, −0.61] | 0.03 | N/A |
Defection | 1 (40/40) | −0.50, [−0.92, −0.08] | 0.02 | N/A |
Adverse events | 1 (33/31) | 0.39, [0.09, 1.65] | 0.2 | N/A |
